Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 935

1.

Archaea dominate oxic subseafloor communities over multimillion-year time scales.

Vuillemin A, Wankel SD, Coskun ÖK, Magritsch T, Vargas S, Estes ER, Spivack AJ, Smith DC, Pockalny R, Murray RW, D'Hondt S, Orsi WD.

Sci Adv. 2019 Jun 19;5(6):eaaw4108. doi: 10.1126/sciadv.aaw4108. eCollection 2019 Jun.

2.

Cardiovascular and Metabolic Toxicity of Abiraterone in Castration-resistant Prostate Cancer: Post-marketing Experience.

Tsao PA, Estes JP, Griggs JJ, Smith DC, Caram MEV.

Clin Genitourin Cancer. 2019 Jun;17(3):e592-e601. doi: 10.1016/j.clgc.2019.03.001. Epub 2019 Mar 12.

PMID:
31023520
3.

The Legacy for Children™ Randomized Control Trial: Effects on Cognition Through Third Grade for Young Children Experiencing Poverty.

Perou R, Robinson LR, Danielson ML, Claussen AH, Visser SN, Scott KG, Beckwith L, Katz L, Smith DC.

J Dev Behav Pediatr. 2019 May;40(4):275-284. doi: 10.1097/DBP.0000000000000656.

PMID:
30921105
4.

Electron Acceleration to MeV Energies at Jupiter and Saturn.

Kollmann P, Roussos E, Paranicas C, Woodfield EE, Mauk BH, Clark G, Smith DC, Vandegriff J.

J Geophys Res Space Phys. 2018 Nov;123(11):9110-9129. doi: 10.1029/2018JA025665. Epub 2018 Nov 9.

5.

Detection of CTC Clusters and a Dedifferentiated RNA-Expression Survival Signature in Prostate Cancer.

Kozminsky M, Fouladdel S, Chung JS, Wang Y, Smith DC, Alva A, Azizi E, Morgan T, Nagrath S.

Adv Sci (Weinh). 2018 Nov 15;6(2):1801254. doi: 10.1002/advs.201801254. eCollection 2019 Jan 23.

6.

A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma.

Pal SK, Forero-Torres A, Thompson JA, Morris JC, Chhabra S, Hoimes CJ, Vogelzang NJ, Boyd T, Bergerot PG, Adashek JJ, Li H, Yu X, Gartner EM, Carret AS, Smith DC.

Cancer. 2019 Apr 1;125(7):1124-1132. doi: 10.1002/cncr.31912. Epub 2019 Jan 9.

PMID:
30624766
7.

A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors.

Smith DC, Chugh R, Patnaik A, Papadopoulos KP, Wang M, Kapoun AM, Xu L, Dupont J, Stagg RJ, Tolcher A.

Invest New Drugs. 2019 Aug;37(4):722-730. doi: 10.1007/s10637-018-0714-6. Epub 2018 Dec 28.

PMID:
30591982
8.

Tuning recombinant protein expression to match secretion capacity.

Horga LG, Halliwell S, Castiñeiras TS, Wyre C, Matos CFRO, Yovcheva DS, Kent R, Morra R, Williams SG, Smith DC, Dixon N.

Microb Cell Fact. 2018 Dec 22;17(1):199. doi: 10.1186/s12934-018-1047-z.

9.
10.

Impact of summer season on pre-hospital time delays in women and men undergoing primary percutaneous coronary intervention.

Gebhard CE, Gebhard C, Maafi F, Bertrand MJ, Stähli BE, Maredziak M, Bengs S, Haider A, Zhang ZW, Smith DC, Ly HQ.

Sci Total Environ. 2019 Mar 15;656:322-330. doi: 10.1016/j.scitotenv.2018.11.363. Epub 2018 Nov 26.

PMID:
30513423
11.

Midwifery presence in United States medical centers and labor care and birth outcomes among low-risk nulliparous women: A Consortium on Safe Labor study.

Neal JL, Carlson NS, Phillippi JC, Tilden EL, Smith DC, Breman RB, Dietrich MS, Lowe NK.

Birth. 2018 Nov 11. doi: 10.1111/birt.12407. [Epub ahead of print]

PMID:
30417436
12.

Influence of midwifery presence in United States centers on labor care and outcomes of low-risk parous women: A Consortium on Safe Labor study.

Carlson NS, Neal JL, Tilden EL, Smith DC, Breman RB, Lowe NK, Dietrich MS, Phillippi JC.

Birth. 2018 Nov 9. doi: 10.1111/birt.12405. [Epub ahead of print]

PMID:
30414200
13.

Towards a 3D GeSbTe phase change memory with integrated selector by non-aqueous electrodeposition.

Huang R, Kissling GP, Kashtiban R, Noori YJ, Cicvarić K, Zhang W, Hector AL, Beanland R, Smith DC, Reid G, Bartlett PN, de Groot CHK.

Faraday Discuss. 2019 Feb 18;213(0):339-355. doi: 10.1039/c8fd00126j.

PMID:
30411749
14.

Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037).

Mitchell TC, Hamid O, Smith DC, Bauer TM, Wasser JS, Olszanski AJ, Luke JJ, Balmanoukian AS, Schmidt EV, Zhao Y, Gong X, Maleski J, Leopold L, Gajewski TF.

J Clin Oncol. 2018 Sep 28:JCO2018789602. doi: 10.1200/JCO.2018.78.9602. [Epub ahead of print]

15.

A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors.

Jimeno A, Moore KN, Gordon M, Chugh R, Diamond JR, Aljumaily R, Mendelson D, Kapoun AM, Xu L, Stagg R, Smith DC.

Invest New Drugs. 2019 Jun;37(3):461-472. doi: 10.1007/s10637-018-0665-y. Epub 2018 Sep 19.

PMID:
30229512
16.

Castration remains despite decreasing definitive treatment of localized prostate cancer in the elderly: A case for de-implementation.

Skolarus TA, Caram ME, Chapman CH, Smith DC, Hollenbeck BK, Hawley S, Tsodikov A, Sales A, Wittmann D, Zaslavsky A.

Cancer. 2018 Oct 15;124(20):3971-3974. doi: 10.1002/cncr.31665. Epub 2018 Sep 7. No abstract available.

PMID:
30192374
17.

Thermal Atomic Layer Etching of Silica and Alumina Thin Films Using Trimethylaluminum with Hydrogen Fluoride or Fluoroform.

Rahman R, Mattson EC, Klesko JP, Dangerfield A, Rivillon-Amy S, Smith DC, Hausmann D, Chabal YJ.

ACS Appl Mater Interfaces. 2018 Sep 19;10(37):31784-31794. doi: 10.1021/acsami.8b10899. Epub 2018 Sep 4.

PMID:
30179460
18.

A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma.

Phillips T, Barr PM, Park SI, Kolibaba K, Caimi PF, Chhabra S, Kingsley EC, Boyd T, Chen R, Carret AS, Gartner EM, Li H, Yu C, Smith DC.

Invest New Drugs. 2019 Apr;37(2):297-306. doi: 10.1007/s10637-018-0655-0. Epub 2018 Aug 22.

19.

Multimodal imaging provides insight into targeted therapy response in metastatic prostate cancer to the bone.

Hoff BA, Brisset JC, Galbán S, Van Dort M, Smith DC, Reichert ZR, Jacobson JA, Luker GD, Chenevert TL, Ross BD.

Am J Nucl Med Mol Imaging. 2018 Jun 5;8(3):189-199. eCollection 2018.

20.

E. coli strain engineering for the production of advanced biopharmaceutical products.

Selas Castiñeiras T, Williams SG, Hitchcock AG, Smith DC.

FEMS Microbiol Lett. 2018 Aug 1;365(15). doi: 10.1093/femsle/fny162.

PMID:
29982628
21.

Substance use outcomes for mindfulness based relapse prevention are partially mediated by reductions in stress: Results from a randomized trial.

Davis JP, Berry D, Dumas TM, Ritter E, Smith DC, Menard C, Roberts BW.

J Subst Abuse Treat. 2018 Aug;91:37-48. doi: 10.1016/j.jsat.2018.05.002. Epub 2018 May 20.

PMID:
29910013
22.

Development of a generic β-lactamase screening system for improved signal peptides for periplasmic targeting of recombinant proteins in Escherichia coli.

Selas Castiñeiras T, Williams SG, Hitchcock A, Cole JA, Smith DC, Overton TW.

Sci Rep. 2018 May 3;8(1):6986. doi: 10.1038/s41598-018-25192-3.

23.

Weather and risk of ST-elevation myocardial infarction revisited: Impact on young women.

Gebhard C, Gebhard CE, Stähli BE, Maafi F, Bertrand MJ, Wildi K, Fortier A, Galvan Onandia Z, Toma A, Zhang ZW, Smith DC, Spagnoli V, Ly HQ.

PLoS One. 2018 Apr 9;13(4):e0195602. doi: 10.1371/journal.pone.0195602. eCollection 2018.

24.

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study.

Gettinger S, Horn L, Jackman D, Spigel D, Antonia S, Hellmann M, Powderly J, Heist R, Sequist LV, Smith DC, Leming P, Geese WJ, Yoon D, Li A, Brahmer J.

J Clin Oncol. 2018 Jun 10;36(17):1675-1684. doi: 10.1200/JCO.2017.77.0412. Epub 2018 Mar 23.

PMID:
29570421
25.

Optimizing host cell physiology and stress avoidance for the production of recombinant human tumour necrosis factor α in Escherichia coli.

Selas Castiñeiras T, Williams SG, Hitchcock A, Cole JA, Smith DC, Overton TW.

Microbiology. 2018 Apr;164(4):440-452. doi: 10.1099/mic.0.000622. Epub 2018 Feb 14.

PMID:
29458685
26.

Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature.

Singhal U, Wang Y, Henderson J, Niknafs YS, Qiao Y, Gursky A, Zaslavsky A, Chung JS, Smith DC, Karnes RJ, Chang SL, Feng FY, Palapattu GS, Taichman RS, Chinnaiyan AM, Tomlins SA, Morgan TM.

Mol Cancer Res. 2018 Apr;16(4):643-654. doi: 10.1158/1541-7786.MCR-17-0539. Epub 2018 Feb 16.

27.

Exploration of the Smallest Diameter Tin Nanowires Achievable with Electrodeposition: Sub 7 nm Sn Nanowires Produced by Electrodeposition from a Supercritical Fluid.

Bartlett PN, Beanland R, Burt J, Hasan MM, Hector AL, Kashtiban RJ, Levason W, Lodge AW, Marks S, Naik J, Rind A, Reid G, Richardson PW, Sloan J, Smith DC.

Nano Lett. 2018 Feb 14;18(2):941-947. doi: 10.1021/acs.nanolett.7b04330. Epub 2018 Feb 2.

PMID:
29356551
28.

Probing Excitons, Trions, and Dark Excitons in Monolayer WS2 Using Resonance Raman Spectroscopy.

McDonnell LP, Huang CC, Cui Q, Hewak DW, Smith DC.

Nano Lett. 2018 Feb 14;18(2):1428-1434. doi: 10.1021/acs.nanolett.7b05184. Epub 2018 Jan 11.

PMID:
29297693
29.

Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.

Hussain M, Daignault-Newton S, Twardowski PW, Albany C, Stein MN, Kunju LP, Siddiqui J, Wu YM, Robinson D, Lonigro RJ, Cao X, Tomlins SA, Mehra R, Cooney KA, Montgomery B, Antonarakis ES, Shevrin DH, Corn PG, Whang YE, Smith DC, Caram MV, Knudsen KE, Stadler WM, Feng FY, Chinnaiyan AM.

J Clin Oncol. 2018 Apr 1;36(10):991-999. doi: 10.1200/JCO.2017.75.7310. Epub 2017 Dec 20.

30.

Streamlining Adverse Events Reporting in Oncology: An American Society of Clinical Oncology Research Statement.

Levit LA, Perez RP, Smith DC, Schilsky RL, Hayes DF, Vose JM.

J Clin Oncol. 2018 Feb 20;36(6):617-623. doi: 10.1200/JCO.2017.75.8193. Epub 2017 Dec 13. No abstract available.

PMID:
29236570
31.

Clinical and genetic analysis of spinocerebellar ataxia type 7 (SCA7) in Zambian families.

Atadzhanov M, Smith DC, Mwaba MH, Siddiqi OK, Bryer A, Greenberg LJ.

Cerebellum Ataxias. 2017 Nov 29;4:17. doi: 10.1186/s40673-017-0075-5. eCollection 2017.

32.

Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy.

Hovelson DH, Liu CJ, Wang Y, Kang Q, Henderson J, Gursky A, Brockman S, Ramnath N, Krauss JC, Talpaz M, Kandarpa M, Chugh R, Tuck M, Herman K, Grasso CS, Quist MJ, Feng FY, Haakenson C, Langmore J, Kamberov E, Tesmer T, Husain H, Lonigro RJ, Robinson D, Smith DC, Alva AS, Hussain MH, Chinnaiyan AM, Tewari M, Mills RE, Morgan TM, Tomlins SA.

Oncotarget. 2017 Sep 22;8(52):89848-89866. doi: 10.18632/oncotarget.21163. eCollection 2017 Oct 27.

33.
34.

Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours.

Schöffski P, Gordon M, Smith DC, Kurzrock R, Daud A, Vogelzang NJ, Lee Y, Scheffold C, Shapiro GI.

Eur J Cancer. 2017 Nov;86:296-304. doi: 10.1016/j.ejca.2017.09.011. Epub 2017 Oct 20.

35.

A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors.

Jimeno A, Gordon M, Chugh R, Messersmith W, Mendelson D, Dupont J, Stagg R, Kapoun AM, Xu L, Uttamsingh S, Brachmann RK, Smith DC.

Clin Cancer Res. 2017 Dec 15;23(24):7490-7497. doi: 10.1158/1078-0432.CCR-17-2157. Epub 2017 Sep 27.

36.

Integrative clinical genomics of metastatic cancer.

Robinson DR, Wu YM, Lonigro RJ, Vats P, Cobain E, Everett J, Cao X, Rabban E, Kumar-Sinha C, Raymond V, Schuetze S, Alva A, Siddiqui J, Chugh R, Worden F, Zalupski MM, Innis J, Mody RJ, Tomlins SA, Lucas D, Baker LH, Ramnath N, Schott AF, Hayes DF, Vijai J, Offit K, Stoffel EM, Roberts JS, Smith DC, Kunju LP, Talpaz M, Cieślik M, Chinnaiyan AM.

Nature. 2017 Aug 17;548(7667):297-303. doi: 10.1038/nature23306. Epub 2017 Aug 2.

37.

A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma.

Vergote IB, Smith DC, Berger R, Kurzrock R, Vogelzang NJ, Sella A, Wheler J, Lee Y, Foster PG, Weitzman R, Buckanovich RJ.

Eur J Cancer. 2017 Sep;83:229-236. doi: 10.1016/j.ejca.2017.06.018. Epub 2017 Jul 26.

38.

Directional connectivity in the EEG is able to discriminate wakefulness from NREM sleep.

Lioi G, Bell SL, Smith DC, Simpson DM.

Physiol Meas. 2017 Aug 22;38(9):1802-1820. doi: 10.1088/1361-6579/aa81b5.

PMID:
28737503
39.

High-Resolution Genetic and Physical Mapping of the Eastern Filbert Blight Resistance Region in 'Jefferson' Hazelnut (Corylus avellana L.).

Sathuvalli V, Mehlenbacher SA, Smith DC.

Plant Genome. 2017 Jul;10(2). doi: 10.3835/plantgenome2016.12.0123.

40.

Self-rated health among multiracial young adults in the United States: findings from the add health study.

Tabb KM, Gavin AR, Smith DC, Huang H.

Ethn Health. 2019 Jul;24(5):495-511. doi: 10.1080/13557858.2017.1346175. Epub 2017 Jun 28.

PMID:
28658965
41.

Substance use prevention and treatment outcomes for emerging adults in non-college settings: A meta-analysis.

Davis JP, Smith DC, Briley DA.

Psychol Addict Behav. 2017 May;31(3):242-254. doi: 10.1037/adb0000267. Epub 2017 Mar 20.

PMID:
28318279
42.

Academic Cancer Center Phase I Program Development.

Frankel AE, Flaherty KT, Weiner GJ, Chen R, Azad NS, Pishvaian MJ, Thompson JA, Taylor MH, Mahadevan D, Lockhart AC, Vaishampayan UN, Berlin JD, Smith DC, Sarantopoulos J, Riese M, Saleh MN, Ahn C, Frenkel EP.

Oncologist. 2017 Apr;22(4):369-374. doi: 10.1634/theoncologist.2016-0409. Epub 2017 Mar 17.

43.

Peer victimization and substance use among African American adolescents and emerging adults on Chicago's Southside.

Hong JS, Voisin DR, Cho S, Smith DC, Resko SM.

Am J Orthopsychiatry. 2018;88(4):431-440. doi: 10.1037/ort0000247. Epub 2017 Mar 13.

PMID:
28287779
44.

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.

de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, Kaye S, Sachdev J, Heymach J, Smith DC, Henshaw JW, Herriott A, Patterson M, Curtin NJ, Byers LA, Wainberg ZA.

Cancer Discov. 2017 Jun;7(6):620-629. doi: 10.1158/2159-8290.CD-16-1250. Epub 2017 Feb 27.

45.

Molecular modeling in the age of clinical genomics, the enterprise of the next generation.

Prokop JW, Lazar J, Crapitto G, Smith DC, Worthey EA, Jacob HJ.

J Mol Model. 2017 Mar;23(3):75. doi: 10.1007/s00894-017-3258-3. Epub 2017 Feb 15.

46.

Sensitivity and specificity of the gain short-screener for predicting substance use disorders in a large national sample of emerging adults.

Smith DC, Bennett KM, Dennis ML, Funk RR.

Addict Behav. 2017 May;68:14-17. doi: 10.1016/j.addbeh.2017.01.013. Epub 2017 Jan 6.

PMID:
28088053
47.

Testing a Matching Hypothesis for Emerging Adults in Project MATCH: During-Treatment and One-Year Outcomes.

Davis JP, Bergman BG, Smith DC, Kelly JF.

J Stud Alcohol Drugs. 2017 Jan;78(1):140-145.

48.

Meta-Analyses of the Effects of Standardized Handoff Protocols on Patient, Provider, and Organizational Outcomes.

Keebler JR, Lazzara EH, Patzer BS, Palmer EM, Plummer JP, Smith DC, Lew V, Fouquet S, Chan YR, Riss R.

Hum Factors. 2016 Dec;58(8):1187-1205. Epub 2016 Oct 17.

PMID:
27821676
49.

Directly Comparing Handoff Protocols for Pediatric Hospitalists.

Lazzara EH, Riss R, Patzer B, Smith DC, Chan YR, Keebler JR, Fouquet SD, Palmer EM.

Hosp Pediatr. 2016 Dec;6(12):722-729. Epub 2016 Nov 1.

50.

Informed Assent Recall Among Adolescents in Substance Use Disorder Treatment Research.

Davis JP, Lux EA, Smith DC, Cleeland L.

J Child Adolesc Subst Abuse. 2016;25(5):417-427. Epub 2016 May 4.

Supplemental Content

Loading ...
Support Center